From promise to practice: showcasing the perceived clinical utility of idiographic networks for eating disorders with complex post-traumatic sequelae
Abstract
Background: Eating Disorders (EDs) are highly heterogeneous and often comorbid conditions that likely contribute to the suboptimal recovery rates achieved with manualized treatments. EDs with complex Post-Traumatic Stress Disorder (cPTSD) are particularly challenging, as these disorders may reinforce one another. Compassion-Focused Therapy for EDs (CFT-E) recently showed optimistic long-term efficacy in a randomized controlled trial (RCT) for EDs with cPTSD; however, the individual pathways to change vary, even within the ED-cPTSD subgroup. One method for tailoring treatment to the individual is through idiographic symptom networks from longitudinal data. However, it is to date indefinite how personalized networks can be clinically applied to the treatment of ED-cPTSD.
Aim: We aim to discuss the perceived clinical utility and implications of personalized networks in routine clinical care for patients with ED-CPTSD.
Methods: This perspective paper presents a case series illustrating the use of personalized network dynamics based on data from five female inpatients receiving CFT-E in an RCT. We examined 13 symptom trajectories, resulting in individual network visualizations that highlight closely aligned symptom trajectories over time.
Results: The five personalized networks showed substantial heterogeneity in symptom dynamics, with each patient displaying a distinct pattern of central symptoms, ranging from tightly interconnected affect-avoidance clusters to more…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.